Proactive Investors
07 Jul 2026, 06:27 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Coiled Therapeutics has developed a new lipid-based softgel formulation of its lead drug AO-252 to overcome absorption limitations of the previous tablet version. — Improving drug bioavailability and delivery consistency is a critical technical derisking step for a clinical-stage oncology candidate.
+0.40Phase I data for AO-252 showed a clinical benefit rate of 80% for twice-daily dosing versus 40% for once-daily dosing in ovarian and endometrial cancer patients. — Strong early signal of efficacy provides a fundamental bullish catalyst for the company's valuation.
+0.30Arrow Exploration Corp has brought its Icaco-2 well in Colombia online, producing approximately 830 barrels per day gross. — Direct increase in corporate production output to 5,000 boepd represents an immediate increase in cash flow and asset value.
+0.30Continue reading
6 related stories
Search tags
Coiled Therapeutics plans to enroll up to 30 patients in targeted dose expansion cohorts for ovarian and prostate cancer by Q4 2026. — Sets a clear timeline for the next set of material clinical data readouts.
+0.20Which stocks this story touches
The company has developed a new oral formulation to improve drug absorption and reports encouraging early clinical results.
The company brought a new well on production, increasing total corporate output.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
14h ago
